Emerging Markets At Stake As Viehbacher Departs Sanofi?
This article was originally published in PharmAsia News
As emerging markets represent 32% of Sanofi’s overall sales, the highest among big pharma firms, will the sudden departure of Viehbacher leave a dent in one of the firm’s key growth platforms?
You may also be interested in...
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.
The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.